At NVIDIA GTC Paris, Europe-based healthcare and life sciences companies are showcasing themselves as leaders in global healthcare innovation, demonstrating their ability to deliver transformative, AI-driven impact at a time when the continent needs it most.
Aimed at addressing staffing shortages, aging populations and rising costs, their diverse efforts across biopharma, population health and digital medicine are supported by the NVIDIA Inception program for startups, which provides cutting-edge startups with benefits including access to the latest developer tools, technical training and exposure to venture capital firms.
Whether building the world’s largest biodiversity database or deploying intelligent agents and AI factories that accelerate discovery and patient care, here’s how European companies are tapping the NVIDIA BioNeMo platform, NVIDIA DGX Cloud and the NVIDIA Cloud Partner network to drive better health outcomes for the region and beyond.
Basecamp Research’s AI-Ready Genomics Database Breaks the Data Wall
London-based Inception startup Basecamp Research has unveiled BaseData, the world’s largest and most diverse biological dataset for generative AI in life sciences.
Built from samples collected at over 125 locations in 26 countries, BaseData contains more than 938 billion new biological sequences and over a million previously unknown species — making it 30x faster, and growing up to 1000x faster — than UniRef 50, a public database that’s been used to train more than 80% of all biological sequence models.
This resource is now being used to train next-generation foundation models using NVIDIA BioNeMo Framework on the NVIDIA DGX Cloud Lepton platform.
By collaborating with NVIDIA, Basecamp has overcome the bottlenecks of scale, diversity and data governance that have traditionally held back commercial biopharma research. Its approach — combining a new data supply chain, global partnerships and GPU-accelerated workflows — enables the retraining of new classes of biological foundation models with the goal of unlocking generalizable biological design and accelerating drug discovery.
With this milestone, Basecamp is setting a new industry benchmark for data-driven AI in biosciences and laying the groundwork for generative biology breakthroughs.
“Data-optimal scaling is the key to overcoming the real-world limitations of current biological models,” said Phil Lorenz, chief technology officer at Basecamp Research. “Combined with NVIDIA’s compute and AI stack, we’re training models that can understand and generate biology like never before.”
Intelligent Agents Transform Healthcare Delivery in UK
Guy’s and St. Thomas’ NHS Foundation Trust — the largest NHS Trust in the U.K., with over 2.8 million patient contacts a year — is launching the Proactive and Accessible Transformation of Healthcare initiative, aka PATH, in collaboration with global investment company General Catalyst and Inception startups Hippocratic AI and Sword Health.
PATH seeks to transform care delivery by integrating advanced AI agents, helping to reduce specialty care waitlists, improve pain management and streamline triage.
“PATH aims to deliver better, faster and fairer healthcare for all,” said Ian Abbs, CEO of Guy’s and St. Thomas’. “By combining cutting-edge technology, including AI, with clinical care, we can build a more proactive NHS.”
This initiative brings together Hippocratic AI’s conversational agents that automate tasks like patient outreach, history-taking and referral validation with Sword Health’s AI Care platform, which has treated over 500,000 patients globally across physical pain, pelvic health and other clinical areas, delivering 6.5 million AI sessions to date.
“Our safety-focused generative AI agents can enable healthcare abundance in the U.K.,” said Munjal Shah, founder and CEO of Hippocratic AI. “With more personalized care, patients can feel more supported and heard, improving outcomes.”
“Our AI Care platform transforms the way care is delivered, turning waiting lists into recovery journeys,” said Virgílio Bento, founder and CEO of Sword Health. “Together, we can reduce waste in healthcare and materially improve clinical outcomes.”
PATH will explore solutions to address the U.K.’s elective care crisis, with more than 53,000 patients waiting for a first appointment at Guy’s and St. Thomas’ alone. By prioritizing cases based on clinical need and enabling timely intervention, PATH aims to design a blueprint for national-scale, AI-driven healthcare transformation.
“The goal of PATH is to enable the NHS to work better for everyone,” said Chris Bischoff, managing director at General Catalyst. “By deploying applied AI to increase access, improve care, optimize resources and empower staff, we believe we can build an NHS fit for the future.”
Pangaea Data’s AI Platform Closes Care Gaps Across Hard-to-Diagnose Diseases
Pangaea Data, an Inception company based in London and San Francisco, is helping close care gaps by discovering patients who are untreated and under-treated despite available intelligence in their existing medical records.
Pangaea’s platform is powered by the NVIDIA NeMo Agent toolkit, an open-source library for profiling and optimizing connected teams of AI agents. Pangaea is also adopting NVIDIA NIM microservices to harness large language models that can help identify patients with rare and prevalent hard-to-diagnose diseases.
These tools help calculate clinical scores required to discover patients with such diseases — involving non-specific features such as fever, nausea and headache — in a manner which emulates a clinician’s manual review process for higher accuracy.
“The NeMo Agent toolkit and NVIDIA NIM microservices enable us to reduce the time taken to configure our platform for each disease condition from weeks to a single day, helping accelerate our mission of improving patient outcomes globally,” said Vibhor Gupta, founder and CEO of Pangaea Data.
Pangaea helps global pharmaceutical providers, health systems and policymakers transform care for better outcomes and increased health equity.
Its platform is now being deployed across health systems in the U.S., U.K., Spain and Barbados as a key part of a population health initiative led by the Prime Minister of Barbados.
Sofinnova, Cure51 and Next-Generation Startups Tap NVIDIA DGX Cloud
Through NVIDIA DGX Cloud Lepton, top European healthcare and life sciences venture capital firms like Sofinnova are bolstering AI-native startups.
As part of this initiative, selected VCs can offer their top portfolio companies early access to DGX Cloud Lepton — including access to 25 NVIDIA H100 GPU nodes for three months, plus white-glove support — to help them scale into new markets requiring sovereign, localized compute.
DGX Cloud is already used by startups like Paris-based Cure51, U.K.-based Sensible Biotechnologies and U.K.-based Molecular Glue Labs (MGL) through an Inception program benefit.
Cure51, a Sofinnova portfolio company, achieved a 17x speedup in genomic analysis and 2x cost savings by shifting workloads to NVIDIA BioNeMo running on DGX Cloud.
Using NVIDIA’s sovereign AI infrastructure through the NVIDIA Cloud Partner network, Sensible reduced its optimization cycles for cell-based mRNA therapeutics design from 15 days to just one, while MGL validated new protein engineering approaches. This program demonstrates how regional innovation labs and cloud partners can empower early-stage biotech.
Learn more about NVIDIA Inception startups advancing AI for healthcare and life sciences in Europe at NVIDIA GTC Paris, taking place June 10-12 at VivaTech.
Watch the NVIDIA GTC Paris keynote from NVIDIA founder and CEO Jensen Huang at VivaTech, and explore GTC Paris sessions.
See notice regarding software product information.